ClinicalTrials.Veeva

Find clinical trials for Eczema in Atlanta, GA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Dyssomnias
Parasomnias
Food Hypersensitivity
Hypersensitivity
Psoriasis

Eczema trials near Atlanta, GA, USA:

Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial (DISCOVER)

The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema...

Enrolling
Atopic Eczema
Moderate-to-Severe Atopic Dermatitis
Other: Topical emollient (moisturizer)
Drug: dupilumab

Phase 4

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Atlanta, Georgia, United States and 29 other locations

This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 52 weeks by subjects with atopic dermatitis (eczema)....

Active, not recruiting
Atopic Dermatitis Eczema
Drug: ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%

Phase 3

Arcutis Biotherapeutics
Arcutis Biotherapeutics

Sandy Springs, Georgia, United States and 91 other locations

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) pre...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab

Phase 3

Lilly
Lilly

Sandy Springs, Georgia, United States and 41 other locations

The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atop...

Enrolling
Atopic Dermatitis
Drug: Lebrikizumab

Phase 3

Lilly
Lilly

Sandy Springs, Georgia, United States and 47 other locations

This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atop...

Enrolling
Atopic Dermatitis
Drug: ADX-914
Drug: Placebo

Phase 2

Q32 Bio

Sandy Springs, Georgia, United States and 39 other locations

Locations recently updated

This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).

Enrolling
Atopic Dermatitis Eczema
Drug: ANB032
Drug: Placebo

Phase 2

AnaptysBio
AnaptysBio

Atlanta, Georgia, United States and 77 other locations

The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...

Active, not recruiting
Atopic Dermatitis
Drug: Dupilumab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Sandy Springs, Georgia, United States and 83 other locations

This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or a...

Enrolling
Atopic Dermatitis
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

Phase 3

Incyte
Incyte

Marietta, Georgia, United States and 105 other locations

Global Assessment for Atopic Dermatitis (vIGA-AD).Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Eczema...

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

Phase 3

Amgen
Amgen

Sandy Springs, Georgia, United States and 196 other locations

, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity Index (EASI)....

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

Phase 3

Amgen
Amgen

Atlanta, Georgia, United States and 234 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems